Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Leronlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Leronlimab | PRO140|PRO 140|anti-CCR5 antibody | Leronlimab is a monoclonal antibody that targets CCR5, which potentially induces killing of tumor cells expressing CCR5, inhibits invasion and metastasis, and reduces tumor burden (Cancer Res 2020;80(4 Suppl):Abstract nr PD4-04). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03838367 | Phase Ib/II | Carboplatin + Leronlimab | Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | Unknown status | USA | 0 |